Multicenter evaluation of analytical characteristics of the Elecsys® Periostin immunoassay

Palme, Stefan; Christenson, Robert H.; Jortani, Saeed A.; Ostlund, Richard E.; Kolm, R; Kopal, Guido; Laubender, Ruediger Paul

doi:10.1016/j.clinbiochem.2016.10.002

Cited by 28 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to address the fact that many of the studies discussed use different assays to measure periostin and report different levels, we have performed a comparison between two of the most published and characterized methods; the assay developed by Izuhara and colleagues and the Elecsys ® periostin assay developed by Roche Diagnostics . There was a strong correlation between results obtained using the two techniques, although the ShinoTest assay consistently detected higher levels than the Roche Elecsys ® assay.…”

Section: Discussionmentioning

confidence: 99%

Serum periostin relates to type‐2 inflammation and lung function in asthma: Data from the large population‐based cohort Swedish GA(2)LEN

James

Janson

Malinovschi

et al. 2017

Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Serum periostin relates to type‐2 inflammation and lung function in asthma: Data from the large population‐based cohort Swedish GA(2)LEN

James

Janson

Malinovschi

et al. 2017

Allergy

View full text Add to dashboard Cite

show abstract

“…Additionally, a number of periostin assays have been used in asthma research, of which only two have published data with respect to stability and variability 36,37 , and none are commercially available for clinical practice currently. To justify its development as a commercially available test, periostin must show its value as uniquely superior to other type-2 biomarkers in identifying asthma phenotypes which preferentially respond to specific asthma treatments and monitor their response to such treatments.…”

Section: Barcelona Respiratory Networkmentioning

confidence: 99%

The Clinical Relevance of Periostin in Asthma

Braithwaite¹,

Semprini²,

Beasley³

2018

BRN

View full text Add to dashboard Cite

Periostin is a matricellular protein which is generated by airway epithelial cells in response to interleukin (IL)-4 and IL-13. Serum periostin levels have been proposed as a biomarker of type-2 inflammation with clinical utility in severe asthma. Normal reference ranges have been established in a predominant Caucasian population using the Elecsys ® Periostin immunoassay. Periostin levels do not differentiate asthma from non-asthma, or mild-to-moderate asthma from severe asthma, although they are higher in adults with asthma who have raised levels of blood eosinophils and fractional exhaled nitric oxide (FeNO). Periostin status can predict response to monoclonal antibody therapy directed against IL-13 and immunoglobulin E (IgE), such that adults with severe asthma and a periostin level ≥ 50 ng/ml (designated "periostin-high") have a greater therapeutic response than "periostin-low" patients. The clinical relevance of these findings is uncertain, due to the similar predictive ability of the more commonly available biomarkers blood eosinophils and/or FeNO. (BRN Rev. 2018;4(4):258-73)

show abstract

“…This is probably related to the decreases of length growth, the increased periostin serum values in small childhood being mainly related to its secretion in bone tissue [37]. As a consequence, [14]. Taking all these considerations into account, periostin values are exposed to multiple variables.…”

Section: Periostin and Bronchial Asthmamentioning

confidence: 99%

“…Bronchial asthma is a chronic inflammatory disease affecting more than 334 million people all over the world [14]. The involvement of periostin in type II inflammatory reaction is currently under intense study, in order to improve the therapeutic means in asthmatic disease, mainly in patients diagnosed with severe type of bronchial asthma, with unfavorable response to corticosteroid therapy.…”

Section: Periostin and Bronchial Asthmamentioning

confidence: 99%

See 1 more Smart Citation

Periostin in bronchial asthma – a brief update

Grigoraș¹,

Lozneanu²,

Grigoraş³

et al. 2017

Arch Clin Cases

View full text Add to dashboard Cite

Periostin is an extracellular matrix protein which intervenes in the regulation of angiogenesis, and in tumoral cells proliferation and invasion. Recent studies, mainly experimental models, have demonstrated the intervention of this molecule in asthmatic disease, by eosinophils recruitment, bronchial wall remodeling, and by stimulation of inflammatory cytokines production. Currently, periostin is considered a marker of type 2 inflammation in asthma, being secreted by respiratory epithelial cells triggered by IL-13 and IL-4. Concomitantly, periostin accumulated at the bronchial epithelial-connective tissue interface is involved in fibrogenesis and mucus secretion, in correlation with the intensity of bronchial mucosa eosinophilic inflammatory infiltrate. However, the intimate molecular mechanisms of periostin involvement in the pathogenic pathway of asthmatic diseases is far away from elucidation, further research being necessary to certify its value as a biomarker useful in diagnosis and in establishment of therapeutic schemes in bronchial asthma.

show abstract

Multicenter evaluation of analytical characteristics of the Elecsys® Periostin immunoassay

Abstract: The performance evaluation of the Elecsys Periostin immunoassay including a multicenter precision analysis demonstrated that the assay is suitable for measuring serum periostin at clinically important concentrations around 50ng/mL.

Cited by 28 publications

References 24 publications

Serum periostin relates to type‐2 inflammation and lung function in asthma: Data from the large population‐based cohort Swedish GA(2)LEN

Serum periostin relates to type‐2 inflammation and lung function in asthma: Data from the large population‐based cohort Swedish GA(2)LEN

The Clinical Relevance of Periostin in Asthma

Periostin in bronchial asthma – a brief update

Contact Info

Product

Resources

About